Financial StabilityMIST has sufficient cash on hand to get through the PDUFA date, whether the review is two months or six months, providing financial stability.
Market PotentialMilestone Pharmaceuticals is developing Cardamyst for the treatment of paroxysmal supraventricular tachycardia, and it has the potential to keep patients out of the emergency room, with peak sales potential in excess of $700M, if approved.
Regulatory ProgressThe company has resubmitted its filing for Cardamyst nasal spray for paroxysmal supraventricular tachycardia (PSVT), indicating progress in addressing previous regulatory issues.